Nombre del producto:2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

IUPAC Name:2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

CAS:1211443-61-6
Fórmula molecular:C14H17ClN4O
Pureza:97%
Número de catálogo:CM103621
Peso molecular:292.77

Unidad de embalaje Stock disponible Precio($) Cantidad
CM103621-5g in stock --
CM103621-10g in stock --
CM103621-25g in stock --
CM103621-100g in stock --

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1211443-61-6
Fórmula molecular:C14H17ClN4O
Punto de fusión:-
Código de sonrisas:CN(C)C(=O)C1=CC2=C(N=C(Cl)N=C2)N1C1CCCC1
Densidad:
Número de catálogo:CM103621
Peso molecular:292.77
Punto de ebullición:
Nº Mdl:MFCD20527881
Almacenamiento:

Category Infos

Pyrrolopyrimidines
Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.
Cyclopentanes
Cyclopentane is a cycloalkane, an organic compound with a molecular formula of C5H10, a colorless and transparent liquid, insoluble in water, soluble in most organic solvents such as ethanol, ether, benzene, carbon tetrachloride, acetone, etc. It is mainly used as a solvent and chromatographic reference materials.
Cyclopentanes,where to buy Cyclopentanes
Cyclopentanes
Cyclopentane (also called C pentane) is a highly flammable alicyclic hydrocarbon with chemical formula C5H10 and CAS number 287-92-3, consisting of a ring of five carbon atoms each bonded with two hydrogen atoms above and below the plane. It occurs as a colorless liquid with a petrol-like odor.

Column Infos

Ribociclib
FDA has approved Novartis Kisqali(ribociclib) to reduce risk of recurrence in people with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-) early breast cancer (EBC).
Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Beyond today’s FDA approval of Kisqali for EBC patients in the US, regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China.

Related Products